Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human soluble receptor for advanced glycation end products
- Development stage
- Preclinical
- Lead developer
- Mater Research
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Oral, Subcutaneous
01
Overview
Recombinant human soluble receptor for advanced glycation end products (sRAGE) is a recombinant protein decoy receptor being developed for the prevention and treatment of type 1 diabetes and other inflammatory conditions. sRAGE represents the soluble extracellular domain of the membrane-bound receptor for advanced glycation end products (RAGE). It acts by binding and sequestering circulating RAGE ligands, such as advanced glycation end products (AGEs), high mobility group box 1 (HMGB1), and S100 proteins, preventing them from engaging cell-surface RAGE and triggering downstream pro-inflammatory signaling cascades. Preclinical research led by Mater Research and the University of Queensland has demonstrated that short-term administration of sRAGE can expand functional regulatory T cells (Tregs), reduce pancreatic islet inflammation, and delay or prevent the onset of autoimmune diabetes.
- Other names
- recombinant human sRAGErh-sRAGEsoluble RAGEsoluble receptor for advanced glycation end productssRAGE
02
Targets
HMGB1 (High mobility group protein B1)S100A8 (S100 calcium-binding protein A8)S100A9 (Myeloid-related protein 14)
Beyond the preview
Go deeper on recombinant human soluble receptor for advanced glycation end products.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human soluble receptor for advanced glycation end products.